Michael Postow
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Postow as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05289193 · CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaMemorial Sloan Kettering Cancer Center · active not recruiting · Melanoma, Melanoma Stage III · principal investigator
- Ph2NCT03122522 · A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyMemorial Sloan Kettering Cancer Center · active not recruiting · Metastatic Melanoma · principal investigator
- Ph1NCT03026517 · Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaMemorial Sloan Kettering Cancer Center · completed · Melanoma · principal investigator
- Ph1NCT02659540 · Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaLudwig Institute for Cancer Research · completed · Melanoma · study chair
- Ph2NCT01252251 · RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal MelanomaMemorial Sloan Kettering Cancer Center · completed · Uveal Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:10 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med · 20156,463 citationsRCR 203.2
- Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med · 20133,396 citationsRCR 92.1
- 2,979 citationsRCR 97.1
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med · 20152,291 citationsRCR 67.7
- 1,500 citationsRCR 40.5
- 1,411 citationsRCR 40.2
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- 774 citationsRCR 23.4
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.N Engl J Med · 2025540 citationsRCR 120.6
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.Sci Transl Med · 2018505 citationsRCR 14.5